Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Probiotic treatment of atopic dermatitis is widely studied with controversial results. The objective of this study is to review the efficacy of probiotics for the treatment of atopic dermatitis in infants. PubMed, Embase, and Cochrane Central Register of Controlled Trials databases, and reference lists were searched up to July 2017. Double-blinded randomized clinical trials were included. The primary outcome was the Scoring Atopic Dermatitis index. Subgroups analyses were conducted on probiotic species, treatment duration, participant age, and disease severity. Eight clinical trials (741 infants) were included in the quantitative synthesis. The overall pooled change in Scoring Atopic Dermatitis index (95% CI) in infants was -5.71 (-8.37, -3.04), P < 0.01. Subgroup analysis revealed that the effect was protective in moderate-to-severe patients -8.32 (-16.35, -0.28), with preparations containing Lactobacillus -5.76 (-9.21, -2.30). Probiotics for the treatment of infantile atopic dermatitis is beneficial.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ijd.13873 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Human YKL-40 antibody alleviates atopic dermatitis-like skin inflammation by inhibiting exosome secretion via the JAK3/STAT6 pathway.
Arch Pharm Res
September 2025
College of Pharmacy and Medical Research Center, Chungbuk National University, 194-21, Osongsaengmyeong 1-ro, Osong-eup, Cheongju-si, Chungcheongbuk-do, 28160, Republic of Korea.
Atopic dermatitis (AD) is an inflammatory skin disease that produces a variety of inflammatory cytokines and chemokines. Chitinase-3-like protein 1 (CHI3L1, YKL-40) significantly contributes to AD-associated inflammatory response and is highly expressed in patients with AD. Therefore, this study elucidated the effects and potential mechanisms of human YKL-40 antibody on AD-affected skin.
View Article and Find Full Text PDFAtopic Dermatitis on TikTok: A Cross-Sectional Analysis of Content Quality and SoC Representation.
J Cutan Med Surg
September 2025
FACET Dermatology, Toronto, ON, Canada.
Thunberg root extract inhibits atopic dermatitis-like skin symptoms.
Allergol Immunopathol (Madr)
September 2025
Inflamm-Aging Translational Research Center, Ajou University Medical Center, Suwon, Republic of Korea;
Thunberg is a perennial herbaceous plant of the genus that belongs to the Apiaceae family and is effective in improving inflammation, gout, and dizziness. However, the skin pruritus improvement effect and mechanism of action of Thunberg root extract (PJRE) have not yet been reported. We investigated the effects of PJRE on the regulation of pruritus and inflammatory responses in compound 48/80 (C48/80)-treated mice, phorbol 12-myristate 13-acetate (PMA)/A23187-induced human skin mast cells, and LPS-stimulated mouse macrophages.
View Article and Find Full Text PDFCardiovascular Comorbidities in Atopic Dermatitis: A Case Report on the Impact of Dupilumab on Skin and Heart Function.
Cureus
August 2025
Department of Dermatology, Poznan University of Medical Sciences, Poznan, POL.
Atopic dermatitis (AD) is a chronic inflammatory skin condition often complicated by cardiovascular comorbidities, impacting treatment options and outcomes. In this paper, we present a 41-year-old patient with severe AD, asthma, and chronic heart failure, who responded well to dupilumab, showing significant improvements in skin severity scores and heart function. This case underscores the effectiveness of dupilumab in managing AD alongside complex comorbidities.
View Article and Find Full Text PDFUpadacitinib Therapy in Adolescent Severe Alopecia Areata: A Case Series and Narrative Review.
Clin Cosmet Investig Dermatol
September 2025
Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, 100730, People's Rep
Purpose: Alopecia areata (AA) is a common, immune-mediated, non-scarring form of hair loss. Janus kinase inhibitors provide considerable insight into the treatment of severe AA. However, the efficacy and safety of upadacitinib treatment of adolescents and pediatric patients with severe AA is unclear, especially in those without concomitant atopic diseases.
View Article and Find Full Text PDF